About This Notebook

The scope

Agility Peptide works through the published research on four peptides studied for recovery and tissue repair: BPC-157, TB-500, GHK-Cu, and KLOW, with BPC-157 leading. It sets out to make a scattered, frequently overstated, and technically dense literature legible — to lay out, in plain language and with citations, what each compound was really tested for, in which species, at what effect sizes, and how far the evidence genuinely carries.

The reason to read the four together is that each comes at repair from a different mechanistic angle — angiogenesis for BPC-157, cytoskeletal dynamics and cell migration for TB-500 (Tβ4), matrix synthesis and copper delivery for GHK-Cu, and inflammatory-signal suppression for the KPV in the KLOW blend — so the four side by side draw a fuller picture than any one on its own. Every compound gets its own page, a comparison page ranges them together, and a shared references list holds every cited source.

The working method

Three habits shape the notebook.

Every claim is pinned to peer review. Each statement carries a numbered citation from PubMed-indexed journals, reviews, and clinical-trial reports, with DOIs or PubMed/PMC links kept on the references page. A finding that comes from a review, not a primary study, is cited as a review.

Evidence is logged at true strength. Doses appear exactly as studied — for example, 2 mg/kg in male Wistar rats — never rescaled to humans or offered as a tip. Where the data are preclinical, single-lab, or rest on a parent molecule rather than the marketed compound (as TB-500 does relative to full-length Tβ4), the page says so outright. That plainness about the limits is the point of the notebook.

Entries cross-reference. Because angiogenesis, actin-driven migration, collagen synthesis, and NF-kB inflammation recur from one compound to the next, the pages link together so a reader can follow a single mechanism across entries.

What it isn't

Agility Peptide is no store, no clinic, and no source of medical advice. Nothing is sold, supplied, sourced, or brokered here — no peptide, no research chemical — and no affiliate or referral tie connects it to any vendor. No clinicians work the pages, no conditions are diagnosed, and nothing is prescribed; no dose, schedule, or route is named for anyone, and an animal-study amount is never presented as a human plan.

The compounds here are research chemicals. None is an approved medicine for systemic human use, and two — BPC-157 and TB-500 — are expressly banned in sport; because the KLOW blend contains TB-500, it is off-limits anywhere anti-doping rules apply. A reader with clinical interests should take them to a licensed clinician in their own jurisdiction, working from regulated, evidence-based options. What the site provides is a calm, data-forward map of the published literature — nothing beyond that.